All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-01-30T00:00:00.000Z

CPX-351 therapy for less fit patients with untreated AML

Jan 30, 2018
Share:

Bookmark this article

In a letter to the Editor of Haematologica, Roland B. Walter [member of the AGP North American Steering Committee] , from the Fred Hutchinson Cancer Research Center, Seattle, WA, and colleagues reported results from a phase II randomized study (NCT01804101), which evaluated attenuated doses of CPX-351, a liposomal formulation of daunorubicin and cytarabine co-encapsulated at a molar ratio of 1:5, in medically less fit patients with untreated AML with a Treatment Related Mortality (TRM) score of > 13.1.

The main objective of this phase II study was to estimate whether 32 units/m2 or 64 units/m2 or both dose levels of CPX-351 could improve TRM rate (versus the historical rate of 30%) while keeping Complete Remission (CR) rate constant in AML patients with high risk of TRM.

In total, 48 patients with a median age of 70.5 years (range, 39.1 –91.1 years) were enrolled in this study between May 2013 and November 2016. Patients were randomized 1:1 to receive either 32 or 64 units /m2 of CPX-351 on Days 1, 3 and 5 for up to four identical induction/re-induction courses. Patients received a median of two (range: 1 – 6) cycles of CPX-351 therapy. Due to the small sample size, randomization was stratified using a dynamic allocation scheme based on TRM score, cytogenetic risk and presence/absence of secondary disease.

Initially, the first 20 patients enrolled in this study were randomized to receive either doses of CPX-351.

Key findings in the 64 units/m2/dose arm (n = 10):

  • CR and CR with Incomplete Blood Count Recovery (CRi) was achieved in two patients respectively
    • Both patients relapsed (after 27 and 251 days) and died on Day 320 and 364
  • Early death occurred in four (40%) patients by Day 28 due to infections with TRM scores of 14.7, 24.1, 33.4, and 58.1 respectively
  • Median Overall Survival (OS): 6 months
  • Due to early death, accrual in the 64 units/m2/dose arm was terminated

The remaining patients (n = 28) enrolled in this study were administered 32 units/m2 CPX-351

Key findings in the 32 units/m2/dose arm (n = 38):

  • CR was achieved in 10 patient
  • CRi was achieved in one patient
  • Resistant disease was observed in 21 patients
  • Early death rate: 28.9% (11/38)
    • Six patients died due to indeterminate causes
  • Median OS: 3 months
  • Median relapse free survival in responders (n = 11): 7 months

In summary, the optimal treatment dosage of CPX-351 for less-fit AML patients remains unidentified. The authors concluded that this study demonstrates that CPX-351 at 32 or 64 units/m2 failed to lower the TRM rate to 15% compared to the historical control while maintaining CR rate of 30% in patients with high-risk of AML.

  1. Walter R.B. et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. 2017 Dec 4. DOI: 10.3324/haematol.2017.182642. [Epub ahead of print].
More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox